Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.55 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CPN1 | P15169 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25700006 | 1.00 | SLC6A1 (0.55) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL160676 | 1.00 | SLC6A1 (0.55) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21612901 | 0.98 | SLC6A1 (0.53) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL28674662 | 0.95 | SLC6A1 (0.48) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL951872 | 0.89 | HRH3 (0.41) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL1415306 | 0.89 | HRH3 (0.41) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL1034237 | 0.89 | HRH3 (0.41) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL5746780 | 0.89 | SLC6A1 (0.47) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL12964597 | 0.87 | SLC6A1 (0.44) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15904240 | 0.87 | HRH3 (0.40) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025108225-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVE AS PARG INHIBITOR | 上海复星医药（集团）股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| US-20240368194-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023025159-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海领泰生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
| CN-108373476-B | Kinase inhibitor and preparation and application thereof | 成都地奥制药集团有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-108373476-A | A kind of kinase inhibitor and its preparation and application | 成都地奥制药集团有限公司 | 2018-08-07 | — | — | CN | disclosed |
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| CN-102686571-B | tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2015-11-25 | — | — | CN | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2613782-A2 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| CN-102686571-A | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO | 2012-09-19 | — | — | CN | disclosed |
| WO-2012030685-A2 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2010109468-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | MAPI PHARMA HK LIMITED (CN) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MAPK3, MAPK1, MAP3K1 | SLC6A1 3606/4885SLC6A11 3864/4885TSHR 1556/4885 |
| US-20240368194-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | SLC6A1 4649/4885SLC6A11 3867/4885TSHR 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.